Amarin Corporation PLC (AMRN) Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa® and Statin Therapy
5/22/2013 9:50:18 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by